期刊文献+

肾脏巨大血管平滑肌脂肪瘤合并结节性硬化1例报告并文献复习 被引量:1

Giant Angiomyolipoma of the Kidney Associated with Tuberous Sclerosis:a Case Report and Review of the Literature
原文传递
导出
摘要 目的:总结肾脏巨大血管平滑肌脂肪瘤合并结节性硬化的临床及组织病理特点,探讨其诊疗方法及预后情况。方法:回顾性分析1例罕见的肾脏巨大血管平滑肌脂肪瘤合并结节性硬化的临床特征、组织病理学特点以及诊断、治疗方法,同时复习近年来的国内外相关文献。结果:患者于我院行剖腹探查,右肾巨大肿瘤切除术,术后病理示血管平滑肌脂肪瘤。手术后患者恢复良好,症状明显改善,肝肾功能正常。术后3个月复查CT:左肾区与术前比无变化,右肾区未见肿瘤复发。结论:对于巨大肾脏血管平滑肌脂肪瘤合并结节性硬化的患者,手术治疗仍可作为可选择的治疗方法,但其远期预后仍待观察。 Objective: Summary of the clinical and pathological features of renal huge angiomyolipoma associated with tuberous sclerosis,diagnosis,treatment and prognosis.Methods: We analysed a rare case of huge renal angiomyolipoma associated with tuberous sclerosis clinical features,histopathologic features,and diagnosis,treatment,and reviewed relevant literature in recent years.Results: Patients with laparotomy in our hospital,the right kidney huge tumor resection,Pathological examination shows of AML.Good recovery in patients after surgery,symptoms improved significantly,liver and kidney function is normal.After 3 months to review CT: left kidney district preoperative unchanged,the right kidney area no recurrence.Conclusions: For a giant kidney AML with TSC patients,surgery is still available as treatment options,but its long-term prognosis remains to be seen.
出处 《现代生物医学进展》 CAS 2012年第20期3847-3849,3893,共4页 Progress in Modern Biomedicine
基金 北京市自然科学基金(7122134)
关键词 血管平滑肌脂肪瘤 结节性硬化 治疗 预后 Angiomyolipoma Tuberous Sclerosis Treatment Prognosis
  • 相关文献

参考文献20

  • 1Franz DN,Leonard J,Tudor C,et al.Rapamycin causes regression of astrocytomas in tuberous sclerosis complex[J].Ann Neurol,2006,59:490-498.
  • 2El-Hashemite N,Zhang H,Henske EP,et al.Mutation in TSC2and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma[J].Lancet,2003,361:1348-1349.
  • 3Washecka R,Hanna M.Malignant renal tumors in tuberous sclerosis[J].Urology,1991,37:340-343.
  • 4Armada RC,Longchong Ramos M,Marrero P,et al.Embryonal rhab-domyosarcoma associated with tuberous sclerosis[J].Med Pediatr Onc-ol,2002,38:302.
  • 5Inoki K,Corradetti MN,Guan KL.Dysregulation of the TSCmTOR pathway in human disease[J].Nat Genet,2005,37:119-124.
  • 6Bissler JJ,McCormack FX,Young LR,et al.Sirolimus for angiomyol-ipoma in tuberous sclerosis complex or lymphangioleiomyomatosis[J].N Engl J Med,2008,358:140-151.
  • 7Crino PB,Nathanson KL,Henske EP.The tuberous sclerosis complex[J].N Engl J Med,2006,355:1345-1356.
  • 8Roach ES,Gomez MR,Northrup H:Tuberous sclerosis complex cons-ensus conference:Revised clinical diagnostic criteria[J].J Child Neur-ol,1998,13:624-628.
  • 9Jones AC,Shyamsundar MM,Thomas MW,et al.Comprehensive mutation analysis of TSC1and TSC2-and phenotypic correlations in 150families with tuberous sclerosis[J].Am J Hum Genet,1999,64:1305-1315.
  • 10Fleury RN,Damante JH,Soares CT,et al.Malignant fibrous histiocy-toma(undifferentiated high-grade pleomorphic sarcoma)occurring in tuberous sclerosis:A case report[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2007,103:e54-e59.

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部